A bi-paratopic anti-EGFR nanobody efficiently inhibits solid tumour growth

The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target for antibody-based therapy. At present, several anti-EGFR monoclonal antibodies (mAbs) have been successfully used, among which cetuximab and matuzumab. X-ray crystallography data show that these antibodies bind t...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Roovers, Rob C., Vosjan, Maria J.W.D., Laeremans, Toon, el Khoulati, Rachid, de Bruin, Renée C.G., Ferguson, Kathryn M., Verkleij, Arie J., van Dongen, Guus A.M.S., van Bergen en Henegouwen, Paul M. P.
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4197845/
https://ncbi.nlm.nih.gov/pubmed/21520037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.26145
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы